e nao houve desentendimento entre as partes, de acordo com fontes familiarizadas com o assunto.A Orygen pretende investir aproximadamente R$ 500 milhoes para construir uma fabrica e iniciar a producao de medicamentos. A unidade sera instalada na regiao de Campinas (SP). A expectativa e que os primeiros biossimilares produzidos cheguem ao mercado em tres anos.As empresas ja tinham feito um pequeno aporte para comecar o negocio, mas esses valores serao reembolsados e os tres socios farao um rearranjo societario. Procurada, a recem-criada superfarmaceutica confirmou a informacao. "A Orygen Biotecnologia e a Libbs Farmaceutica informam a saida do laboratorio da joint venture formada por Biolab, Cristalia e Eurofarma. As empresas acionistas passam a deter 33,33% de participacao cada. A decisao foi tomada de comum acordo entre as partes."A nova empresa vai manter o projeto original de desenvolver os medicamentos complexos e nao devera procurar um novo socio, de acordo com as mesmas fontes, que tambem negam que esse projeto podera ser desfeito.Desde outubro do ano passado, o bioquimico ingles Andrew Simpson esta a frente da nova companhia. Simpson, com solida carreira academica, deixou o renomado Instituto Ludwig de Pesquisa de Cancer, nos Estados Unidos, para coordenar a superfarmaceutica nacional.Alem da Orygen, o governo federal tambem deu apoio para a Bionovis, joint venture formada entre os laboratorios Ache, Uniao Quimica, Hypermarcas e EMS. Essa empresa, presidida por Odnir Finotti, ex-presidente da ProGenericos, associacao que reune os laboratorios de medicamentos genericos, foi criada no primeiro semestre do ano passado. A companhia ainda estuda onde ira erguer sua fabrica. Os Estados de Santa Catarina e Rio de Janeiro estao no pareo._____________________________________________________________________________The brazilian pharmaceutical company Libbs decided to leave Orygen Biotechnology, super-pharma company created with support from the federal government to produce biologics and biosimilars. The decision was taken at the end of last year. The other laboratories - Eurofarma, Cristalia and Biolab - will keep the company and take the project forward, according to sources consulted by Valor Economico.The company was established last year to produce, initially, seven drugs considered strategic for the government in the areas of oncology and rheumatoid arthritis. The package of remedies imported organic costs about $ 3.5 billion a year to state coffersThe journal valor economico, found that there was incompatibility between the management and the other partners Libbs. One of the four pharmaceutical companies involved, Libbs, whose turnover is around R$ 600 million, is more averse to partnerships. The decision to exit the joint venture's own Libbs broke and there was no disagreement between the parties, according to sources familiar with the matter.The Orygen intends to invest approximately R$ 500 million to build a factory and start production of medicines. The unit will be installed in Campinas (SP). The expectation is that the first biosimilars produced reach the market within three years.The companies had already made a small contribution to get the business, but these values will be refunded and the three partners will make a corporate rearrangement. When contacted, the newly created superfarmaceutica confirmed the information. "The Orygen Biotechnology and Pharmaceutical Libbs lab report output of the joint venture